Maintenance of hematopoietic stem cells (HSCs) within the adult BM is crucial for the healthy production of hematopoietic cells ([@bib36]). HSCs reside in a specialized microenvironment in the BM called the niche ([@bib43]). Along with cell-intrinsic programs, the niche influences the cell fate of HSCs, which in turn govern the homeostasis of the hematopoietic system ([@bib31]). The HSC niche is chiefly composed of nonhematopoietic cells, including immature osteoblasts (OBLs; [@bib3]), endothelial cells (ECs; [@bib8]; [@bib13]), perivascular cells ([@bib46]; [@bib13]), mesenchymal stem cells (MSCs; [@bib28]), sympathetic nervous cells ([@bib23]), adipocytes ([@bib33]), and nonmyelinating Schwann cells ([@bib56]). Nonetheless, mature hematopoietic cells such as macrophages/monocytes ([@bib9]), osteoclasts ([@bib25]), and regulatory T cells ([@bib16]) also regulate HSCs, albeit mainly in an indirect manner, through the modulation of nonhematopoietic niche cells. Recently, mature megakaryocytes (Mks) were described as hematopoietic progeny that directly regulate HSC quiescence ([@bib18]; [@bib7]; [@bib58]; [@bib32]); one of the mechanisms underlying Mk niche function is the production of the cytokine thrombopoietin (Thpo) by Mks themselves ([@bib32]). However, among the Mk-related niche factors reported to date, no molecular mechanism that is specific to Mks has been identified.

Thpo is a crucial cytokine for both the maturation of Mks and the maintenance of quiescent HSCs ([@bib59]; [@bib40]; [@bib57]). Thpo is produced in multiple organs, including the liver, kidney, spleen, and muscle ([@bib34]). Baseline production of serum Thpo is thought to be maintained by the liver and regulated in response to inflammatory stress or changes in glycosylation of aged platelets ([@bib22]; [@bib45]; [@bib17]). Serum Thpo levels also fluctuate according to circulating platelet number: platelets sequester Thpo via the myeloproliferative leukemia virus oncogene (c-Mpl), the receptor for Thpo ([@bib26]; [@bib12]), thereby lowering Thpo levels. Thus, platelet number is not as tightly regulated by Thpo production as erythrocyte number is by erythropoietin production ([@bib14]). It is likely that BM HSCs depend on Thpo, which is produced in the BM by niche cells. Depletion of circulating platelets by neuraminidase does not affect HSCs ([@bib7]), indicating that serum Thpo up-regulation through thrombocytopenia does not affect HSC maintenance. Moreover, HSCs reside near bone-lining OBLs and mature Mks, which both support HSCs by producing Thpo ([@bib57]; [@bib32]). However, the main cellular source of Thpo, upon which BM HSCs depend, and the molecular signaling pathway that mediates BM Thpo production remain elusive.

Recent studies showed that signals mediated through C-type lectin-like domain-containing receptors (CLEC-4H1 and CLEC-4H2; also known as Ashwell--Morell receptor) stimulate Thpo production in hepatocytes through recognition of desialylated platelets ([@bib17]). Platelets and Mks express CLEC-2 ([@bib48], [@bib49]), which is among the top 25 genes specifically expressed on Mks ([@bib44]). Activation of platelet CLEC-2 through binding to sialylated podoplanin is essential for the segregation of lymphatic and blood vessels during development ([@bib6]; [@bib50]). CLEC-2--podoplanin signaling also functions in maintenance of lymphocyte- and dendritic cell--related responses in the stroma of lymph nodes ([@bib1], [@bib2]; [@bib19]).

The significance of CLEC-2 expression on Mks in BM hematopoiesis, and whether it is involved in Thpo production in Mks, has not been previously explored. Here, we demonstrate that Mk-specific deficiency of CLEC-2 disrupts HSC quiescence and alters HSC potential as a result of defective Mk niche function. Moreover, we demonstrate that CLEC-2 signaling is involved in various molecular pathways for production of niche factors, including Thpo in Mks. Through the identification of CLEC-2, a novel Mk-specific factor, our data elucidate the organ-dependent production and function of Thpo and reinforce the idea that Mks contribute to a niche that regulates HSC quiescence.

RESULTS {#s01}
=======

CLEC-2 is highly expressed on BM Mks {#s02}
------------------------------------

CLEC-2 expression was detected in platelets, dendritic cells, and liver sinusoidal endothelia ([@bib51]); however, the expression of CLEC-2 in BM has not been previously investigated. Using immunohistochemistry (IHC), we observed expression of CLEC-2 protein on the surface of Mks and ECs in the BM ([Fig. 1 A](#fig1){ref-type="fig"}). Hematopoietic stem and progenitor cell (HSPC) fractions also expressed *Clec2* transcripts ([Fig. 1 B](#fig1){ref-type="fig"}). Flow cytometry analysis confirmed surface CLEC-2 expression on HSPCs ([Fig. 1 C](#fig1){ref-type="fig"}). CLEC-2 protein expression was also compared in various hematopoietic ([Fig. 1 D](#fig1){ref-type="fig"}) and niche cells ([Fig. 1 E](#fig1){ref-type="fig"}). Among the hematopoietic and niche cells, CLEC-2 expression on CD41^+^ Mks and ECs was significantly high.

![**CLEC-2 is expressed in Mks and is specifically deleted in Mks of *Clec2^MkΔ/Δ^* mice.** (A) IHC of BM of 10-wk-old wild-type mice. CLEC-2 stains for VE-cadherin--positive ECs (arrowheads) and VE-cadherin--negative Mks (arrows). Enlargement of the dotted box is shown in the top right panel. CLEC-2 stains for CD41-positive Mks (bottom right). (B) Relative expression of CLEC-2 (*Clec1b*) transcripts in various hematopoietic cells. (C) Calculation of mean fluorescence ratios of CLEC-2 in various HSPC populations as measured by flow cytometry. (D and E) Mean fluorescence intensity of various hematopoietic (D) and niche (E) cells. (B--E) Means ± SD. *n* = 4; two independent experiments. \*, P \< 0.05; and \*\*, P \< 0.01 by Tukey's test. (F) Detection of *Clec2* deletion by genomic PCR. An intact exon yields a 2,500-bp product, whereas removal of floxed exon 1 results in a 1,200-bp product. (G) Expression of CLEC-2 in platelets and LT-HSCs from *Clec2^MkΔ/Δ^* (Δ/Δ) and *Clec2^+/+^* (+/+) mice. Red, CLEC-2 antibody-stained; blue, isotype control. Means ± SD. *n* = 5; two independent experiments. P = 0.0078 for platelets and P = 0.69 for LT-HSCs by Student's *t* test. (H) IHC of BM staining CLEC-2 and VE-cadherin in *Clec2^MkΔ/Δ^* (Δ/Δ) mice. Bars: (A and H) 100 µm; (A, top right) 25 µm. (I) Measurement of PB parameters in *Clec2^MkΔ/Δ^* (Δ/Δ) and *Clec2^+/+^* (+/+) mice. Means ± SD. *n* = 5; three independent experiments. P-values as indicated by Student's *t* test.](JEM_20150057_Fig1){#fig1}

We investigated mice deficient in CLEC-2 specifically in the Mk lineage (*PF4-Cre:Clec2^flox/flox^* mice \[*Clec2^MkΔ/Δ^*\]), which are born and survive through adulthood ([@bib37]). PCR analysis confirmed that *Clec2* deletion was specific to Mk lineages: deletion was detected in genomic DNA from CD41^+^ (glycoprotein IIb^+^) cells, but not LSK (Lineage negative, Sca-1^+^, c-Kit^+^) cells, in the BM of *Clec2^MkΔ/Δ^* mice ([Fig. 1 F](#fig1){ref-type="fig"}). CLEC-2 protein level was significantly reduced in platelets from *Clec2^MkΔ/Δ^* mice but retained in their long-term HSCs (LT-HSCs; [Fig. 1 G](#fig1){ref-type="fig"}). Deletion of CLEC-2 from Mks was also confirmed with IHC ([Fig. 1 H](#fig1){ref-type="fig"}). *Clec2^MkΔ/Δ^* mice exhibited mild thrombocytopenia along with anemia ([Fig. 1 I](#fig1){ref-type="fig"}).

CLEC-2--deficient mice have impaired Mk cell population {#s03}
-------------------------------------------------------

Because CLEC-2 is highly expressed in Mk lineages, we asked whether CLEC-2 deficiency altered the frequency and BM functions of Mk lineage cells. The frequencies and numbers of mature Mks and Mk progenitors (MkP and Pre MegE cells) were unaltered in *Clec2^MkΔ/Δ^* mice ([Fig. 2, A--D](#fig2){ref-type="fig"}), and total CD41^+^ Mk cell number was unaltered in *Clec2^MkΔ/Δ^* mice ([Fig. 2 E](#fig2){ref-type="fig"}). However, ploidy analysis revealed a reduced frequency of mature polyploid Mks with CLEC-2 deficiency ([Fig. 2, F and G](#fig2){ref-type="fig"}). IHC revealed a significant reduction in the number of Mks in the metaphyseal region of the BM in *Clec2^MkΔ/Δ^* mice ([Fig. 2 H](#fig2){ref-type="fig"}). These observations indicate that CLEC-2 deficiency modestly affects the maturation of Mks but drastically alters the distribution of Mks within the BM.

![**Altered distribution of Mks in BM of *Clec2^MkΔ/Δ^* mice.** (A and B) Representative flow cytometric plots showing Mk progenitor cell population (MkP: Lin^−^cKit^+^Sca-1^−^\[LKS^−^\] CD150^+^CD41^+^; Pre-MegE: LKS^−^FcγR^−^CD105^+^CD150^+^) in *Clec2^MkΔ/Δ^* (Δ/Δ) and *Clec2^+/+^* (+/+) mice. (C--E) Number of MkP (C), Pre-MegE (D), and CD41^+^ Mks (E) in Δ/Δ and +/+ mice. Means ± SD. *n* = 5; two independent experiments. ns, P = 0.46 for C, P = 0.24 for D, and P = 0.24 for E by Student's *t* test. (F and G) Representative flow cytometric plot showing Mks (F) and Mk frequency within the total Mk population (G), based on ploidy analysis of +/+ and Δ/Δ mice. Means ± SD. *n* = 4; two independent experiments. \*, P \< 0.05 by Tukey's test. (H) IHC of BM, staining for ECs (VE-cadherin), Mks (CD41), and DAPI in the metaphysis and diaphysis of +/+ and Δ/Δ mice. Bar, 100 µm.](JEM_20150057_Fig2){#fig2}

CLEC-2--deficient Mks exhibit impaired Thpo production and niche function {#s04}
-------------------------------------------------------------------------

Mks can support HSC expansion in vitro, chiefly through the production of Thpo ([@bib32]). Hence, we asked whether CLEC-2 deficiency would alter the capacity of Mks to support HSCs in vitro. Addition of Mks to HSC cultures resulted in a Thpo-dependent increase in HSC number ([@bib32]). Accordingly, addition of *Clec2^+/+^* Mks to cultured HSCs promoted proliferation, as indicated by expansion of LSK cells and LT-HSCs ([Fig. 3, A and B](#fig3){ref-type="fig"}). *Clec2*-deficient Mks exhibited a reduced capacity to stimulate HSPC proliferation and could not maintain LT-HSC populations ([Fig. 3 B](#fig3){ref-type="fig"}).

![**CLEC-2**--**positive Mks produce Thpo.** (A and B) Effect of 3 d of co-culture with Mks from Δ/Δ or +/+ mice on LSK cells (A) and LT-HSCs (B). Means ± SD. *n* = 4; two independent experiments. \*, P \< 0.05 by Tukey's test. (C) Relative levels of niche factor (*Thpo*, *Angpt1*, *Cxcl12*, *KitL*, *IL-7*, *Vcam1*, *Spp1*, *TnC*, *Tgf-b1*, *Tgf-b2*, *Tgf-b3*, *Fgf1*, and *Pf4*) transcripts in Mks from Δ/Δ mice compared with +/+ mice. (D) Relative levels of *Thpo* transcripts were significantly up-regulated in cultured Mks treated with a CLEC-2 stimulatory antibody. (E) IHC of BM from +/+ and Δ/Δ mice. Mks, which are CD41, exhibit lower Thpo levels in CLEC-2--deficient Mks. Magnification of a representative Mk is shown in the bottom panels. Bars: (top) 50 µm; (bottom) 100 µm. (F) Gene expression of CLEC-2 downstream pathway molecules in Mks from +/+ and Δ/Δ mice. (G) Knockdown of *Syk*, *Lcp2*, and *Plcg2* results in reduced expression of *Thpo* transcript in Mks. (C, D, F, and G) Means ± SD. *n* = 4; two independent experiments. ns, P \> 0.05; \*, P \< 0.05; and \*\*, P \< 0.01 by Student's *t* test.](JEM_20150057_Fig3){#fig3}

Next, we assessed whether *Clec2*-deficient Mks exhibited changes in the production of various niche factors. *Clec2*-deficient Mks exhibited a broad range of decrease in the gene expression of various niche factors, including *Angpt1*, *Cxcl12*, *IL-7*, *Spp1*, *TnC*, and *Pf4* ([Fig. 3 C](#fig3){ref-type="fig"}). Characteristically, *Clec2*-deficient Mks secreted less Thpo and altered Mk niche function. *Clec2*-deficient Mks exhibited significantly lower *Thpo* expression than Mks from *Clec2^+/+^* mice ([Fig. 3 C](#fig3){ref-type="fig"}). Furthermore, wild-type Mks treated with CLEC-2--stimulating antibodies expressed significantly higher levels of *Thpo* transcripts ([Fig. 3 D](#fig3){ref-type="fig"}). The decrease of Thpo protein expression in CLEC-2--deficient Mks was confirmed by IHC ([Fig. 3 E](#fig3){ref-type="fig"}).

Transcript expression of CLEC-2 signaling pathway genes were decreased in CLEC-2--deficient Mks ([Fig. 3 F](#fig3){ref-type="fig"}). To confirm that CLEC-2 signaling affected Thpo production in Mks, we used inducible shRNAs to knock down three downstream molecules involved in CLEC-2 signaling: *Syk*, *Lcp2*, and *Plcg2* ([@bib51]). Cultured LT-HSCs were transduced with lentiviral clones that inducibly express each shRNA and then cultured to obtain CD41^+^Ter119^−^ Mks. Knockdown of *Syk*, *Lcp2*, and *Plcg2* was highly efficient: transcripts of the targeted genes were nearly absent in sorted Mks (not depicted). Knockdown of *Syk*, *Lcp2*, or *Plcg2* significantly decreased the expression of Thpo in the sorted Mks ([Fig. 3 G](#fig3){ref-type="fig"}). These data confirmed that CLEC-2 signaling is indeed critical for Thpo production in Mks.

CLEC-2 deficiency in Mks directly affects HSC cycle quiescence {#s05}
--------------------------------------------------------------

Because CLEC-2--deficient Mks exhibited diminished Thpo production and could not support cultured HSCs, we next assessed whether HSCs in *Clec2^MkΔ/Δ^* mice were affected in vivo. Lineage and HSPC differentiation were unchanged in the BM of *Clec2^MkΔ/Δ^* mice ([Fig. 4, A--C](#fig4){ref-type="fig"}). Functionally, HSPCs from *Clec2^MkΔ/Δ^* mice displayed a significant elevation in colony-forming capacity, indicating an increase in the proliferation capacity of HSPCs ([Fig. 4, D and E](#fig4){ref-type="fig"}). Cell cycle analysis of HSCs, as assessed by Pyronin Y staining, indicated loss of HSC quiescence (Pyronin Y--negative CD34^−^ LSK cells) in *Clec2^MkΔ/Δ^* mice ([Fig. 4, F and G](#fig4){ref-type="fig"}). c-Mpl expression was significantly up-regulated in LT-HSCs from *Clec2^MkΔ/Δ^* mice, suggestive of deficient Thpo signaling ([Fig. 4 H](#fig4){ref-type="fig"}). Loss of nonhematopoietic niche cells (ECs, MSCs, and OBLs) was not observed in BM of *Clec2^MkΔ/Δ^* mice ([Fig. 4, I and J](#fig4){ref-type="fig"}).

![**HSCs from *Clec2^MkΔ/Δ^* mice exhibit reduced stem cell quiescence.** (A--C) Number of BM MNCs (A), lineage composition in the BM (B), and relative number of BM HSPCs (C) in +/+ and Δ/Δ mice. (D and E) CFU-C number (D) and HPP-CFC number (E) of 500 HSCs from Δ/Δ and +/+ mice. (A--E) Means ± SD. *n* = 6; two independent experiments. ns, P \> 0.05; and \*, P \< 0.05 by Student's *t* test. (F) Cell cycle analysis using Pyronin Y and Hoechst 33342 staining of CD34^−^ LSK cells in +/+ and Δ/Δ mice. (G) Cell cycle state of CD34^−^ LSK cells with Pyronin Y staining in +/+ and Δ/Δ mice. (H) Relative levels of *Mpl* transcripts in LT-HSCs from +/+ and Δ/Δ mice. (I and J) Number (I) and frequency (J) of ECs (CD45^−^Ter119^−^CD31^+^), MSCs (CD45^−^Ter119^−^Sca-1^+^ALCAM^−^), and OBLs (CD45^−^Ter119^−^CD31^−^Sca-1^−^ALCAM^+^) in Δ/Δ and +/+ mice. (F--J) Means ± SD. *n* = 4; two independent experiments. ns, P \> 0.05; \*, P \< 0.05; and \*\*, P \< 0.01 by Student's *t* test.](JEM_20150057_Fig4){#fig4}

Although CLEC-2 is also expressed on ECs, EC-specific CLEC-2 deletion did not alter hematopoiesis: *VE-cadherin-Cre:Clec2^floxed/floxed^* mice exhibited no change in peripheral blood (PB) parameters (not depicted), HSPC numbers, HSC quiescence, or repopulation potential (not depicted). These observations indicate that Mk-specific *Clec2* deficiency stimulates HSCs to exit the G~0~ phase of the cell cycle.

HSCs from *Clec2^MkΔ/Δ^* mice exhibit reduced stem cell potential {#s06}
-----------------------------------------------------------------

To further investigate the stem cell potential of HSCs from *Clec2^MkΔ/Δ^* mice, we performed a competitive repopulation assay, using BM transplantation (BMT) of LT-HSCs from *Clec2^+/+^* or *Clec2^MkΔ/Δ^* mice (Ly5.2) into C57BL/6-Ly5.1 recipients. HSCs from *Clec2^MkΔ/Δ^* mice had lower engraftment rates, as assessed by chimerism in PB and BM of various HSPC fractions 4 mo after primary and secondary BMT ([Fig. 5, A--D](#fig5){ref-type="fig"}). No significant difference was noted in the lineage differentiation of engrafted HSCs from *Clec2^+/+^* or *Clec2^MkΔ/Δ^* mice ([Fig. 5 E](#fig5){ref-type="fig"}). Limiting dilution analysis revealed a significantly lower frequency of repopulating HSCs in the BM of *Clec2^MkΔ/Δ^* mice ([Fig. 5 F](#fig5){ref-type="fig"}). HSCs from *Clec2^MkΔ/Δ^* mice did not exhibit defective homing to the BM ([Fig. 5 G](#fig5){ref-type="fig"}). In addition, HSCs from *Clec2^MkΔ/Δ^* mice did not exhibit higher rates of apoptosis, as assessed by Annexin V staining ([Fig. 5 H](#fig5){ref-type="fig"}). Gene set enrichment analysis of LT-HSCs from *Clec2^MkΔ/Δ^* mice revealed altered HSC-related gene expression profiles, notably an enrichment in progenitor cell--related genes, relative to LT-HSCs from *Clec2^+/+^* mice, suggesting enhanced differentiation and a loss of stem cell character of HSCs from *Clec2^MkΔ/Δ^* mice ([Fig. 5 I](#fig5){ref-type="fig"}). These results indicate a loss of stem cell potential in *Clec2^MkΔ/Δ^* mice.

![**HSCs from *Clec2^MkΔ/Δ^* mice exhibit reduced repopulation capacity.** (A and C) Percentage of donor-derived cells (Ly5.2) in PB after the first and second BMT at the indicated time intervals (in months). (B and D) Percentage of donor-derived cells (Ly5.2) in BM HSPCs after the first and second BMT at the indicated time intervals (in months). (A--D) Means ± SEM. *n* = 6; two independent experiments. \*, P \< 0.05; and \*\*, P \< 0.01 by Student's *t* test. (E) Lineage composition of Ly5.2 MNCs in recipient mice. Means ± SEM. *n* = 6; two independent experiments. P \> 0.05 in all groups by Student's *t* test. (F) Extreme limiting dilution assay of BM MNCs from Δ/Δ and +/+ mice. *n* = 7; two independent experiments. P = 0.0432 by Pearson's χ^2^ test. (G) Number of CFSE staining LT-HSCs from Δ/Δ and +/+ mice homing to the BM 24 h after BMT. Note that no significant difference was present in homing capacity of HSCs from Δ/Δ and +/+ mice. (H) Number of Annexin V^+^ HSCs in Δ/Δ and +/+ mice. (G and H) Means ± SD. *n* = 4; two independent experiments. ns, P = 0.677 (G) or P = 0.48 (H) by Student's *t* test. (I) Gene set enrichment analysis of LT-HSCs from Δ/Δ and +/+ mice (*n* = 10). Genes expressed by intermediate and multipotent progenitors were significantly up-regulated in LT-HSCs from Δ/Δ mice (plots are second and third from left). Statistical analysis is as shown in figure.](JEM_20150057_Fig5){#fig5}

*Clec2^MkΔ/Δ^* mice have major developmental vascular defects, chiefly in the lymphatic system ([@bib50]; [@bib15]). To verify that the loss of stem cell potential resulted specifically from *Clec2* deletion in BM Mk lineages, we transplanted BM mononuclear cells (MNCs) from *Clec2^+/+^* or *Clec2^MkΔ/Δ^* mice (Ly5.2) along with BM MNCs from Ly5.1 mice at a 4:1 ratio into lethally irradiated Ly5.1 wild-type mice to test the effect of *Clec2*-deleted Mks on wild-type HSCs ([Fig. 6 A](#fig6){ref-type="fig"}). We observed a high frequency of Ly5.2^+^ Mks in recipient BM ([Fig. 6 B](#fig6){ref-type="fig"}). The number of engrafted Ly5.1 LT-HSCs (CD34^−^Flt-3^−^ HSCs and CD150^+^CD48^−^CD41^−^ \[SLAM\] HSCs) was significantly lower in transplants from *Clec2^MkΔ/Δ^* mouse donors ([Fig. 6 C](#fig6){ref-type="fig"}). Furthermore, the percentage of Ly5.1^+^ Pyronin Y--negative HSCs was significantly lower when *Clec2^MkΔ/Δ^* mice served as donors ([Fig. 6, D and E](#fig6){ref-type="fig"}). Also, both Ly5.1^+^ and Ly5.2^+^ HSCs in the recipient of *Clec2^MkΔ/Δ^* mouse donors stained higher levels of Ki67 ([Fig. 6 F](#fig6){ref-type="fig"}), indicating loss of cell cycle quiescence. These data suggest that the HSC defects exhibited by *Clec2^MkΔ/Δ^* mice are a direct consequence of *Clec2* depletion in Mks.

![**Loss of HSC quiescence in HSCs in *Clec2^MkΔ/Δ^* mice is Mk specific.** (A) Scheme of the experimental model for BMT. 8 × 10^6^ BM MNCs from Δ/Δ and +/+ mice were transplanted into lethally irradiated (Ly5.1) mice along with Ly5.1-positive 2 × 10^6^ BM MNCs. (B) Percentage of Ly5.2-positive Mks in BMs of recipient mice. (C) Relative number of Ly5.1-positive HSPCs in recipient mice. (B and C) Means ± SD. *n* = 10; two independent experiments. ns, P = 0.167; \*, P \< 0.05; and \*\*, P \< 0.01 by Student's *t* test. (D) Ly5.1^+^ Pyronin Y--negative cells in CD34^−^ LSK cells in the BMs of recipient mice. (E) Ly5.1^+^ Pyronin Y--negative cells in CD34^+^ LSK cells in the BMs of recipient mice. (D and E) Means ± SD. *n* = 5; two independent experiments. \*\*, P \< 0.01 by Student's *t* test. (F) Ratio of fluorescence intensity of Ki67 and TOTO-3 on single sorted cells in Ly5.1^+^ or Ly5.2^+^ HSCs in chimeric mice. Means ± SEM. *n* = 50; two independent experiments. \*\*, P \< 0.01 by Student's *t* test.](JEM_20150057_Fig6){#fig6}

Mk-specific CLEC-2 depletion results in extramedullary hematopoiesis {#s07}
--------------------------------------------------------------------

We next asked whether CLEC-2 deficiency affected HSC retention in the BM. *Clec2^MkΔ/Δ^* mice exhibited massive splenomegaly ([Fig. 7, A and B](#fig7){ref-type="fig"}). Both HSC and HSPC number and frequency were elevated in *Clec2^MkΔ/Δ^* mice ([Fig. 7, C--E](#fig7){ref-type="fig"}), indicating that the splenomegaly was caused by extramedullary hematopoiesis. PB of HSC *Clec2^MkΔ/Δ^* mice exhibited increased numbers of LSKs and LT-HSCs ([Fig. 7 F](#fig7){ref-type="fig"}). Furthermore, a significant increase in CFU-C and HPC-CFC was observed in the PB of *Clec2^MkΔ/Δ^* mice ([Fig. 7, G and H](#fig7){ref-type="fig"}), and the distance between LT-HSCs and Mks was significantly higher in *Clec2^MkΔ/Δ^* mice than in *Clec2^+/+^* mice ([Fig. 7 I](#fig7){ref-type="fig"}). These data show that chronic loss of CLEC-2--expressing Mks decreased HSC retention in BM and induced extramedullary hematopoiesis in the spleen.

![***Clec2^MkΔ/Δ^* mice exhibit extramedullary hematopoiesis and elevated mobilization of HSCs into PB.** (A and B) Gross appearance (A) and hematoxylin and eosin staining (B) of spleens from +/+ and Δ/Δ mice. Arrowheads indicate the presence of Mks in *Clec2^Mk+/+^* spleens. Magnification of an Mk is shown in the inset. Bar, 200 µm. (C--E) Analysis of spleen of Δ/Δ and +/+ mice. Spleen weight (C), total MNC number (D), and absolute populations of various HSPC fractions (E) are significantly higher in spleens of *Clec2^MkΔ/Δ^* compared with *Clec2^Mk+/+^* mice. (F--H) Percentage of LSK cells (F), CFU-C number (G), and HPP-CFC number (H) in PB of +/+ and Δ/Δ mice. (C--H) Means ± SD. *n* = 6; two independent experiments. \*\*, P \< 0.01 by Student's *t* test. (I) Quantitation of distance of LT-HSCs from Mks in +/+ and Δ/Δ mice. Means ± SD. *n* = 6; two independent experiments. \*, P = 0.038 by Tukey's test.](JEM_20150057_Fig7){#fig7}

Administration of Thpo rescues HSC phenotypes in *Clec2^MkΔ/Δ^* mice {#s08}
--------------------------------------------------------------------

To determine whether the functional defects in HSCs from *Clec2^MkΔ/Δ^* mice could be attributed to reduced Thpo levels, we administered recombinant Thpo (PEG-rHuMGDF) to both *Clec2^+/+^* and *Clec2^MkΔ/Δ^* mice. Intravenous Thpo injection for four consecutive days restored the number and frequency of polyploid Mks in *Clec2^MkΔ/Δ^* mice ([Fig. 8 A](#fig8){ref-type="fig"}). In agreement with a previous study ([@bib54]), administration of Thpo stimulated proliferation of HSCs, as shown by the increased the percentage of BrdU-positive HSCs and the percentage of Pyronin Y--negative cells in CD34-LSK cells in both *Clec2^+/+^* and *Clec2^MkΔ/Δ^* mice ([Fig. 8, B and C](#fig8){ref-type="fig"}). However, as Thpo administration instigates self-renewal of HSCs, the absolute number and frequency of CD34^−^ Pyronin Y--negative HSCs within the BM were restored ([Fig. 8, D and E](#fig8){ref-type="fig"}). Thpo administration also significantly increased the number of Mks within the BM in both *Clec2^+/+^* and *Clec2^MkΔ/Δ^* mice ([Fig. 8 F](#fig8){ref-type="fig"}). The repopulation potential of HSCs from *Clec2^MkΔ/Δ^* mice significantly increased with Thpo injection, as confirmed by competitive BMT ([Fig. 8, G and H](#fig8){ref-type="fig"}). Thus, the loss of HSC potential in *Clec2^MkΔ/Δ^* mice depended on the defective Thpo production of Mks.

![**Maintenance of HSC quiescence requires Thpo produced by CLEC-2--positive Mks.** (A) Changes in Mk number based on ploidy analysis after intravenous Thpo injection in *Clec2^MkΔ/Δ^* (Δ/Δ) and *Clec2^Mk+/+^* (+/+) mice. Controls were injected with PBS. (B) Change in percentage of BrdU-positive HSCs after intravenous Thpo injection in Δ/Δ and +/+ mice. (A and B) Means ± SD. *n* = 4 (B) or 5 (A); two independent experiments. \*\*, P \< 0.01 by Tukey's test. (C) Representative flow cytometry plot of Pyronin Y and Hoechst 33342 for CD34-LSK cells from Δ/Δ and +/+ mice after administration of PBS or Thpo. Numbers indicate percentage of Pyronin Y--negative cells in CD34-LSK cells. Means ± SD. *n* = 4; two independent experiments. \*, P \< 0.05 by Student's *t* test. (D and E) Total number (D) and frequency (E) of Pyronin Y--negative CD34-LSK cells. Means ± SD. *n* = 4; two independent experiments. \*\*, P \< 0.01 by Tukey's test. Note that Pyronin Y--negative CD34-LSK cell number is restored in *Clec2^MkΔ/Δ^* (Δ/Δ) BM after Thpo injection. (F) IHC of BMs from Δ/Δ and +/+ mice after administration of PBS or Thpo. Bar, 100 µm. (G and H) Percentage of donor-derived cells in PB (G) and BM HSPCs (H) at the indicated intervals after BMT. Means ± SEM. *n* = 6; two independent experiments. \*, P \< 0.05; and \*\*, P \< 0.01 by Tukey's test.](JEM_20150057_Fig8){#fig8}

DISCUSSION {#s09}
==========

In this study, we characterized the niche function of a C-type lectin-like family member, CLEC-2, in Mks. Mks from *Clec2^MkΔ/Δ^* mice exhibited reduced Thpo expression at both the gene and protein level. Knockdown of the CLEC-2 downstream pathway affected the expression of a broad range of niche factors in Mks, characteristically one being Thpo. Mk-specific deletion of CLEC-2 caused a subtle reduction in Mk number but significantly affected HSC quiescence and repopulation potentials. Administration of recombinant Thpo rescued HSC defects in *Clec2^MkΔ/Δ^* mice, indicating that defective Thpo production impaired HSC function in *Clec2^MkΔ/Δ^* mice. Thus, we demonstrated that CLEC-2 is an upstream factor essential for Mk-mediated maintenance of HSCs.

Our results identify Mk CLEC-2 signaling as a novel signaling pathway involved in the production of Thpo in the BM. Systemic Thpo levels depend on sequestration of Thpo by myeloproliferative leukemia protein (c-Mpl), a Thpo receptor, expressed on platelets ([@bib26]). However, Mks in *Clec2^MkΔ/Δ^* mice produced lower levels of Thpo, despite the presence of thrombocytopenia, indicating that systemic Thpo levels determined by the availability of c-Mpl did not affect Mk-produced Thpo for the maintenance of HSCs. It remains controversial whether liver production of Thpo can compensate for reduced systemic levels of this cytokine ([@bib27]; [@bib41]). *Thpo* transcript levels in the liver increase with inflammatory stress and accumulation of desialylated platelets ([@bib55]; [@bib17]) but does not change in thrombocytopenic mouse models ([@bib11]). *Clec2^MkΔ/Δ^* mice exhibited no change in liver *Thpo* transcript levels (unpublished data), indicating that CLEC-2 deficiency did not stimulate liver Thpo production. Therefore, our data indicate that the BM Thpo level is loosely associated with serum and liver Thpo levels and that Mks supply a critical amount of Thpo for maintenance of HSCs in the BM. However, our data do not eliminate the possibility that Thpo production by the BM stroma is necessary to maintain HSCs in the BM. In fact, OBLs produce Thpo ([@bib57]), and the platelet α-granule proteins PDGF and FGF-2 can stimulate expression of Thpo in BM stromal cells in vitro ([@bib47]). Further studies are necessary to clarify the degree to which HSCs rely on locally or systemically produced Thpo.

Although HSCs from *Clec2^MkΔ/Δ^* mice were responsive to exogenous Thpo, indicating that the loss of stem cell potential of HSCs in *Clec2^MkΔ/Δ^* mice was caused by deficiency of Thpo, our data cannot differentiate whether Thpo directly or indirectly affected HSCs through the modulation of Mk number and function. Indeed, exogenous Thpo administration robustly enhances Mk proliferation and Mks can produce various factors other than Thpo that can affect HSC stem cell potential ([@bib7]; [@bib58]). Supporting this, although our analysis revealed Thpo as a prominent niche factor affected by CLEC-2 depletion, CLEC-2 deficiency also affected other niche-related gene expressions (such as *Cxcl12*, *Angpt1*, *Vcam1*, and *Pf4*) in Mks. In addition, CLEC-2--deficient Mks exhibited decrease in various CLEC-2 downstream pathways. These data may indicate that CLEC-2 signaling may be involved in the modulation of a broad range of Mk functions. Our data further position Mks as a potent niche cell but emphasize the need to elucidate the complex niche regulation on HSCs exerted by Mks.

Recent studies showed that specific depletion of Mks disrupts HSC quiescence through different mechanisms. Induced depletion of Mks for 7 d in *PF4-Cre:iDTR* mice chronically activates HSCs to proliferate and self-renew, through either platelet factor 4 (PF4; [@bib7]) or transforming growth factor-β1 (TGF-β1; [@bib58]). In contrast, we showed that acute depletion of Mks in *PF4-Cre:iMos-Csp* mice resulted in disruption of HSC quiescence and repopulation potentials without HSC self-renewal ([@bib32]). These three studies all reported direct Mk regulation of HSCs, yet portrayed Mks as acting in different modes, according to the time point after induction of Mk deletion. Confusing matters further, Mk depletion affected different subsets of HSCs in conflicting ways: CD34^−^Flt3^−^LSK cells exhibit modest or no increase in number, whereas CD150^+^CD105^+^LSK cells expanded up to 15-fold ([@bib7]; [@bib58]). The differences in the HSC niche functions of Mks may be attributed to the fact that depletion of Mks and platelets dramatically changes the levels of multiple factors. CLEC-2 depletion in Mks did not instigate self-renewal of HSCs or significant changes in platelet lineage-biased CD150^+^CD105^+^LSK cells ([@bib39]; unpublished data), but it did reduce the stem cell potential of LT-HSCs (CD34^−^Flt3^−^LSK; [@bib10]). Our study indicates that CLEC-2--mediated Mk regulation of HSCs is not committed to the self-renewal of Mk lineage-biased HSCs, but instead specifically influences the quiescence and stem cell potential of a broader spectrum of HSCs. CLEC-2 may be an Mk-specific niche regulatory factor that shows the long-term effect of Mk regulation on HSC maintenance.

Constitutive deletion of CLEC-2 and conditional deletion of CLEC-2 from Mk/platelet lineages reportedly results in blood and lymphatic vessel dis-separation phenotype ([@bib6]; [@bib50]). Recently, the role of CLEC-2 in lymph node development and adult lymph node maintenance was reported ([@bib19]; [@bib5]). Chimeric mice in which BMs of WT mice were reconstituted with BMs from *Clec2^MkΔ/Δ^* mice have been reported to present hemorrhage in the lymph nodes, indicating that platelet CLEC-2 maintains the integrity of vessels in the adult lymph node. No apparent hemorrhages in the lymph nodes were observed in the chimeric mice in which BMs of *Clec2^MkΔ/Δ^* mice and *Clec2^+/+^* mice was transplanted in a 4:1 ratio, presumably because of the mixture of *Clec2^+/+^* mouse--derived BM (unpublished data). The gross morphology of vasculature in the BM was unaffected in *Clec2^MkΔ/Δ^* mice, and no hemorrhage was observed in the BMs (unpublished data). Moreover, EC-specific deletion of CLEC-2 did not affect hematopoiesis. However, whether deficiency of CLEC-2 in platelets affected the function of BM ECs, especially in association to immune response, should be investigated in the future.

A characteristic finding in the *Clec2^MkΔ/Δ^* mice was the presence of extramedullary hematopoiesis. Thpo is known as a cytokine to induce HSC mobilization ([@bib29]). Accordingly, administration of exogenous Thpo to *Clec2^MkΔ/Δ^* mice increased mobilization of HSCs to PB and did not rescue the extramedullary hematopoiesis phenotype. Therefore, decreased levels of Thpo in *Clec2^MkΔ/Δ^* mice are not causative of the extramedullary hematopoiesis phenotype. The mechanism of how Mks retain HSCs within the BM and how CLEC-2 signaling associates with HSC retention is yet to be investigated.

Mks indirectly regulate HSCs by stimulating OBLs after transplantation ([@bib35]). Mk numbers in *Clec2^MkΔ/Δ^* mice were reduced preferentially in the metaphyseal region of the BM. Podoplanin, an activating ligand of CLEC-2 ([@bib6]), was highly expressed in osteo-lineage cells ([@bib42]). Displacement of Mks in *Clec2^MkΔ/Δ^* mice from the bone-rich metaphysis suggests that CLEC-2 deficiency in Mks may impair Mk and OBL interactions. Furthermore, it indicates that OBLs may indirectly regulate Thpo production in Mks via their expression of podoplanin. Moreover, our findings suggest that CLEC-2--podoplanin signaling may be a novel molecular pathway for niche cell function. Indeed, CLEC-2--deficient Mks exhibited decreased gene expression of CLEC-2 downstream molecules, and knockdown of signals downstream of the CLEC-2--podoplanin interaction (*Syk*, *Lcp2*, and *Plcg2*) confirmed that CLEC-2 signaling is crucial for Mk Thpo production. Loss of sialic acid expression on platelets contributes to Thpo production in the liver ([@bib17]). Because the lectin-like properties of CLEC-2 allow it to interact with sialic acid residues on podoplanin ([@bib38]), our findings provide insight into the involvement of glycosylation in Thpo production.

In summary, our study strongly indicates that Mks function as a niche to maintain HSC quiescence through CLEC-2. These findings could enable manipulation of HSCs and Mks for clinical applications, as well as therapies against diseases related to defects in HSCs and Mks.

MATERIALS AND METHODS {#s10}
=====================

 {#s11}

### Mice {#s12}

All mice were in the C57BL/6 background. *Clec2 ^flox/flox^* mice were described previously ([@bib37]). *PF4-Cre* transgenic mice were provided by R.C. Skoda (University Hospital, Basel, Switzerland; [@bib53]). *Clec2^flox/flox^* mice were crossed with either *PF4-Cre* or *VE-cadherin-Cre* (*VEC-Cre*) transgenic mice (stock 006137 purchased from The Jackson Laboratory) to obtain *PF4-Cre:Clec2^flox/flox^* mice (*Clec2^MkΔ/Δ^*) or *VEC-Cre:Clec2^flox/flox^* mice (*Clec2^ECΔ/Δ^*), respectively. C57BL/6-Ly5.1 or C57BL/6-Ly5.2 mice were used for competitive repopulation assays. Unless specified, 10--12-wk-old mice were used in all experiments. All animal experiments were approved by Keio University and performed in accordance with the Guidelines of Keio University for Animal and Recombinant DNA experiments.

### PB analysis and colony assays {#s13}

PB was collected from the tail vein in a heparinized microtube (Drummond Scientific) and analyzed using CellTac (NIHON KOHDEN). For colony assays and assessment of PB mobilization of HSCs, PB was collected from the inferior vena cava of anesthetized mice using a 27G needle. MNCs from 0.5 ml PB were obtained by centrifugation using Lymphoprep (Axis-Shield) and then used for colony assays. Colony counts for CFU-C and HPP-CFC were assessed on days 7 and 14, respectively.

### Antibodies {#s14}

Primary antibodies used for IHC and flow cytometry were as follows: c-Kit (2B8; eBioscience), CD16/32 (93; eBioscience), VE-cadherin (eBioscience), c-Kit (R&D Systems), Sca-1 (E13-161.7; BioLegend), CD48 (HM48-1; BioLegend), CD150 (TC15-12F12.2; BioLegend), IL-7Rα (SB/199; BioLegend), endoglin (MJ7/18; BioLegend), CD4 (L3T4; BD), CD8 (53-6.72; BD), B220 (RA3-6B2; BD), TER-119 (BD), Gr-1 (RB6-8C5; BD), CD34 (RAM34; BD), Mac-1 (M/70; BD), Flt-3 (A2F10.1; BD), CD41 (MWReg30; BD), CD45.2 (104; BD), CD45.1 (A20; BD), GPIbα (Xia.G5; Emfret), Clec2 (AbD Serotec), and Thpo (Bioss). Secondary antibodies for IHC were Alexa Fluor 488--conjugated IgGs (Molecular Probes) or Cy3/Cy5/DyLight549/DyLight649-conjugated IgGs (Jackson ImmunoResearch Laboratories, Inc.). IHC specimens were treated with DAPI (Molecular Probes) for nuclear staining. Stimulatory rabbit anti--mouse CLEC-2 antibody was a gift of K. Suzuki-Inoue.

### Immunostaining of BM {#s15}

Decalcified BM sections were prepared and stained as described previously ([@bib30]). Frozen sections prepared according to the Kawamoto method ([@bib24]) were used to stain Lin^−^CD41^−^CD48^−^CD150^+^ cells in the BM.

### Confocal microscopy and quantification of fluorescent images {#s16}

Fluorescence images were obtained using a confocal laser-scanning microscope (FV1000; Olympus). Scanning was performed in sequential laser emission mode to avoid scanning at other wavelengths. Images obtained from BM sections were analyzed using the TissueQuest image analysis software (TissueGnostics).

### Flow cytometric analysis, cell cycle analysis, and competitive repopulation assays {#s17}

Flow cytometric analysis and competitive repopulation assays were performed as described previously ([@bib4]). Cell cycle analysis of hematopoietic cells was performed using Pyronin Y staining and short-term BrdU incorporation assays ([@bib52]). For Ki-67 staining, HSCs were sorted and attached to glass slides with sedimentation and subsequently stained for Ki-67 and TOTO-3. Cells were observed under a confocal laser-scanning microscope (FV1000) for measurement of single cell fluorescence intensity and calculated for their relative Ki-67 fluorescence against nuclear stain (TOTO-3).

### BMT {#s18}

BM MNCs (4 × 10^5^ cells) from C57BL/6-Ly5.1 mice, together with LT-HSCs (5 × 10^2^ cells) from the indicated mice (Ly5.2), were transplanted into lethally irradiated C57BL/6-Ly5.1 congenic mice. Secondary transplantations into lethally irradiated C57BL/6-Ly5.1 congenic mice were performed using 2 × 10^6^ BM MNCs from primary recipients. Recipient mice were sacrificed for analysis 4 mo after BMT. For extreme limiting dilution assays ([@bib20]), lethally irradiated Ly5.1 mice were transplanted with 10^4^, 2 × 10^4^, or 3 × 10^4^ BM MNCs from either *Clec2^+/+^* or *Clec2^MkΔ/Δ^* mice along with 2 × 10^5^ Ly5.1 competitor cells. PB chimerism for the limiting dilution assay was assessed 12 wk after transplantation.

### In vitro HSC and Mk co-cultures {#s19}

Mature Mks (B220^−^Mac-1^−^Gr-1^−^CD41^+^) were obtained from mouse BM as described previously ([@bib18]). LT-HSCs (Lin^−^c-Kit^+^Sca-1^+^Flt-3^−^CD34^−^) sorted from Ly5.1 mice were co-cultured for 3 d with Mks in SF-O3 medium (Sankyo Junyaku) supplemented with murine recombinant SCF (100 ng/ml) with or without human recombinant Thpo (100 ng/ml) and then analyzed ([@bib21]). LT-HSCs and Mks were cultured at a 1:1 ratio. Mks were cultured for 2 d to obtain conditioned medium for the indicated experiments. To inhibit Thpo activity, a recombinant mouse ThpoR (Mpl) Fc chimera (0.4 µg/ml; R&D Systems) was added to the culture. An IgG Fc fragment (0.4 µg/ml; Jackson ImmunoResearch Laboratories, Inc.) served as a control. For knockdowns in Mks, MISSION custom vectors (Sigma-Aldrich) were used.

### In vivo Thpo assays {#s20}

For in vivo stimulation of Thpo signaling, recombinant human Thpo (PEG-rHuMGDF; [@bib21]; donated by Kyowa Hakko Kirin Co., Ltd.) was administered. Mice were treated with either 100 µg/kg (i.v.) of PEG-rHuMGDF or human IgG Fc fragment (Jackson ImmunoResearch Laboratories, Inc.). For rescue experiments, *Clec2^MkΔ/Δ^* mice were treated for four consecutive days.

### Quantitative PCR assay {#s21}

Isolated RNA was reverse transcribed with Superscript VILO (Invitrogen). Quantitative PCR assays were performed using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems), SYBR Premix Ex Taq (Takara Bio Inc.), and primer sets for each gene (Takara Bio Inc.). Values obtained were normalized to β-actin expression and expressed as fold induction relative to control samples.

### Genomic PCR assay {#s22}

Genomic DNA was isolated from sorted cells using NucleoSpin (Takara Bio Inc.), and PCR was conducted using 5′-ACGTATCTCTGAACATCCAAGAAAG-3′ and 5′-CTGATCTTACCTGCATTCCATTAGT-3′ as primers.

### Gene set enrichment analysis {#s23}

Total RNA was extracted from LT-HSCs (Lin^−^cKit^+^Sca-1^+^CD34^−^Flt-3^−^) from *Clec2^Mk+/+^* and *Clec2^MkΔ/Δ^* mice. Total RNA was purified using an RNeasy Mini kit (QIAGEN). Microarray processing was performed by DNA Chip Research Inc. Normalized expression data were assessed using GSEA v2.0.13 software (Broad Institute). Gene sets used were PARK_HSC_VS_MULTIPOTENT_PROGENITORS_DN, PARK_HSC_VS_MULTIPOTENT_PROGENITORS_UP, PARK_HSC_MARKERS, PARK_HSC_AND_MULTIPOTENT_PROGENITORS, IVANOVA_HEMATOPOIESIS_STEM_CELL, GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP, GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS, BAKKER_FOXO3_TARGETS_UP, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM, IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, and JAATINEN_HEMATOPOIETIC_STEM_CELL_DN, obtained from the Molecular Signatures Database v4.0 available at the GSEA web site. The number of permutations was set at 1,000. Gene sets with nominal p-value \<0.05 and a false discovery rate q-value (FDR-q) \<0.25 were considered statistically significant.

### Statistical analysis {#s24}

All results are expressed as means ± SD unless otherwise specified. Statistical significance was determined by Tukey's multiple comparison test. The two-tailed Student's *t* test was used for two-group comparisons. All experiments were conducted and confirmed in at least two replicates.
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